At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 23 enrolled
Drug / intervention
BI 10773 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relative Bioavailability of Multiple Oral Doses of BI 10773 (25 mg) and Ramipril (5 mg) Administered Together Compared to Multiple Oral Doses of BI 10773 (25 mg) Alone and Ramipril (5 mg) Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Three Way Crossover, Clinical Phase I Study)
In Brief
A Phase 1 clinical trial evaluating BI 10773 and Ramipril for Healthy. Completed, enrolled 23 participants across 1 site.
Detailed Summary
Primary objective:To investigate if BI 10773 affects the pharmacokinetics of ramipril and if ramipril affects the pharmacokinetics of BI 10773.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionMar 2011
TodayJul 2026
First PostedJan 27, 2011
Enrollment StartJan 1, 2011
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.4 years ago
Interventions
BI 10773drug
medium dose, oral administration
Ramiprildrug
Medium dose oral administration on day 2-5
BI 10773drug
medium dose oral administration
Ramiprildrug
Low dose oral administration on day 1
Ramiprildrug
Low dose oral administration on day 1
Ramiprildrug
Medium dose oral administration on day 2-5